跳至主要内容
临床试验/NCT00442741
NCT00442741撤回1 期

An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)

Novartis Pharmaceuticals0 个研究点开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
主要终点
To evaluate the safety, tolerability and potential activity of patupilone once every 21 days in patients that completed the core study

研究概览

简要总结

The purpose of this extension study is to evaluate the potential inhibitory effects of patupilone on metabolism using midazolam and omeprazole as the respective probe drugs.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Patupilone + Midazolam

Experimental

干预措施: Patupilone (Drug)

Patupilone + Omeprazole

Experimental

干预措施: Patupilone + Omeprazole (Drug)

结局指标

主要结局

To evaluate the safety, tolerability and potential activity of patupilone once every 21 days in patients that completed the core study

次要结局

  • Assessment of objective response and tumor evaluation will be based on the response evaluation criteria in solid tumors (RECIST)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验